2 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Lomustine: new trials by email Literature Review of Lomustine trials Research Report on Lomustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma trabedersen, temozolomide, Drug delivery system for administration of AP 12009 - Anaplastic Astrocytoma, Glioblastoma | Phase 3 | Terminated | Isarna Therapeutics GmbH | 27 | 2008-12-01 | 2014-11-14 |
Astrocytoma (2) · Glioblastoma (2) · Brain Neoplasms (1) · Glioma (1) · Neoplasms (1) · Recurrence (1)
Isarna Therapeutics GmbH (1) · Tocagen Inc. (1)
Canada (2) · South Korea (2) · United States (2) · Argentina (1) · Austria (1) · Brazil (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Mexico (1) · Poland (1) · Russia (1) · Spain (1)
Rolando Del Maestro, MD, PhD (1) · Timothy Cloughesy, MD (1)